Surv BioPharma Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $13.9M

  • Investors
  • 16

Surv BioPharma General Information

Description

Developer of gene therapies designed to improve the treatment of various diseases. The company's platform utilizes drug delivery systems and targeted therapy approaches, aiming to enhance drug efficacy while minimizing side effects, enabling healthcare providers to offer precise and effective treatments to patients in need of specialized medical care.

Contact Information

Website
www.survbiopharma.co.jp
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 8-35-1 Sakuragaoka, Kagoshima University Graduate School of Medical and Dental Sciences
  • 1st Floor, Medical and Dental Sciences Building 5
  • Kagoshima, Kagoshima 890-8544
  • Japan
+81
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 8-35-1 Sakuragaoka, Kagoshima University Graduate School of Medical and Dental Sciences
  • 1st Floor, Medical and Dental Sciences Building 5
  • Kagoshima, Kagoshima 890-8544
  • Japan
+81

Surv BioPharma Timeline

2023202420252026
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Surv BioPharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 23-Dec-2025 $13.9M Completed Generating Revenue
2. Early Stage VC 28-Dec-2022 Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view Surv BioPharma’s complete valuation and funding history, request access »

Surv BioPharma Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Class A Preferred
To view Surv BioPharma’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Surv BioPharma Patents

  • 3

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • Pending

  • Expiring in next 12 mo

Surv BioPharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-7868817-B2 Shb-egf intensive therapy for diabetes Active 02-Apr-2024
JP-7816735-B2 Oncolytic viruses and cancer treatment using the same Active 22-Jan-2024
JP-7536364-B2 Pharmaceutical composition for treating bone and soft tissue tumors Active 19-May-2021 A61K35/761

Surv BioPharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Surv BioPharma Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
FFG Venture Business Partners Corporate Venture Capital Minority
Fujita Innovation Capital Corporate Venture Capital Minority
Fukuoka Jisho Holding Company Minority
Higin Capital Investment Bank Minority
Japan Venture Capital Venture Capital Minority
You’re viewing 5 of 16 investors. Get the full list »

Ready to get started?

Request a free trial

Surv BioPharma FAQs

  • When was Surv BioPharma founded?

    Surv BioPharma was founded in 2022.

  • Where is Surv BioPharma headquartered?

    Surv BioPharma is headquartered in Kagoshima, Japan.

  • What is the size of Surv BioPharma?

    Surv BioPharma has 12 total employees.

  • What industry is Surv BioPharma in?

    Surv BioPharma’s primary industry is Drug Discovery.

  • Is Surv BioPharma a private or public company?

    Surv BioPharma is a Private company.

  • What is the current valuation of Surv BioPharma?

    The current valuation of Surv BioPharma is .

  • What is Surv BioPharma’s current revenue?

    The current revenue for Surv BioPharma is .

  • How much funding has Surv BioPharma raised over time?

    Surv BioPharma has raised $21.3M.

  • Who are Surv BioPharma’s investors?

    FFG Venture Business Partners, Fujita Innovation Capital, Fukuoka Jisho, Higin Capital, and Japan Venture Capital are 5 of 16 investors who have invested in Surv BioPharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process